YES1 and lung carcinoma: A phase two, sequentially enrolled, multicohort, multicenter, nonrandomized, open-label research showed that dabrafenib plus trametinib provides a novel therapy with clinically meaningful antitumor activity and a potential safety profile for previous untreated BRAFV600E-mutant NSCLC patients (Planchard et al., 2017).A study has shown that YES1 acts as a predictive biomarker promotes the proliferation and progression of lung cancer and provides support for the clinical evaluation of dasatinib treatment (Garmendia et al., 2019).